Hepatitis Awareness lecture held at JSMU (sponsored by Searle Biosciences Pvt, Ltd.)
Hepatitis Screening camp at Health Expo, 2017
Local Conference participation by SBPL
SEARLE INFUSIONS AND DISPOSABLES
MEDECO IV Cannulae
MEDECO Inject Insulin
MEDECO Auto Disable (RUP) Syringe (aproved supplier of WHO and UNICEF)
MEDECO Standard Syringe
Medeset Single use I.V Infusion set (basic and Y port)
SEARLE – NS (Macsol NS) IV Infusion (1000ml, 500ml, 100ml, 50ml, 20ml)
SEARLE – DS (Macsol DS) IV Infusion (1000ml, 500ml)
SEARLE – DS 1/2 (Macsol DS) IV Infusion (500ml)
SEARLE – 5% (Macsol 5%) IV Infusion (1000ml, 500ml, 100ml)
SEARLE – RL (Macsolate D) IV infusion (1000ml, 500ml)
SEARLE – PEADS (Macsol Peads) IV Infusion (500ml)
PROTiEX Surgical Gloves – Powdered (all ranges)
PROTiEX Surgical Gloves – Powder free (all ranges)
PROTiEX Examination Gloves (all ranges)
GLOBAL BUSINESS DIVISION
GBD is one of the strategic business divisions of The Searle Company Limited. At present we are operating in 17 countries while the ground-work on a few more countries of the African Region (East and West Africa) is underway for commercialization. Searle has already formed legal entities, to expand its global business, in Switzerland, Spain, UK, UAE, Malaysia, Philippines, Vietnam and recently in Belgium.
The progress has paced up significantly in the recent past opening new vistas of business opportunity and growth for the whole group. Considering the strategic importance of this division in catalysing the growth and establishing corporate image world-wide, the base facilities have been addressed and are in the wake of modernization to cope up with the global challenges.
Searle GBD stands proudly amongst the Top 4 Exporters of Pharmaceutical Products from Pakistan out of a Total of 540 Exporters. Searle jumped from 15th position in 2013-14 to 4th position in 2017-18 & achieved 1.1 Billion PKR in 2017-18 with a CAGR of 65%.
Afghanistan which literally means Land of Afghans is a mountainous, land-locked country located in South-Central Asia.
The Searle Company Limited commenced marketing and sales operations in Afghanistan decades ago. The company operates in Afghanistan with well-trained teams dedicated to provide quality medicine to the people of Afghanistan. We are among the top 5 players of the pharmaceutical industry of Afghanistan with quality products among major therapeutics areas including Cardio-Metabolic,
Gastroenterology, Antibiotics, Pain Management, Psychiatry, Rheumatology and others.
Sri Lanka is located in South-East part of India and a naturally beautiful country which inhabits many wildlife species. It is one of the SAARC countries where pharmaceutical market is dominated by South Asian companies. Its pharmaceutical market size is more than USD$ 300 million. Currently, there are more than 400 registered pharmaceutical exporters and 7-10 local manufacturing companies which operate in Sri Lanka. Searle is growing at a pace of 4-5 times higher than the market growth and improved its ranking from 89 to 69 in the last three years and made it to 6th largest pharmaceutical among Pakistani companies in IMS MAT Q1, 2018. Searle has also established its Cardio-Metabolic, Respiratory, Gastroenterology and Psychiatry segments and almost having all the brands in top 10-tier which ultimately gave a recognition among the healthcare providers in Sri Lanka.
Activities of Sri Lanka
Myanmar, being the largest country in mainland Southeast Asia has a population of 57 million. It has a pharmaceutical market size of over USD$400million with a CAGR of 13-14%. Myanmar’s pharmaceutical market is mainly dependent upon imports from South Asia & ASEAN region.
Searle’s Myanmar operation started back in 2000 on a trading model with transition to marketing model in 2015. As per the import data of Myanmar-2017, Searle is one of the largest exporter of pharmaceutical products from Pakistan. Aimed at continued growth and expansion in various therapeutic segments, Searle Myanmar has an established portfolio in Anti-infective, Psychiatry, Cardio-metabolic, Gastroenterology, Pain Management, ENT and Respiratory segments.
Activities of Myanmar
Vietnam is a rising economy with a population of about 97 million, located in Southeast Asia on the South China Sea and known for its beaches, rivers, Buddhist pagodas and bustling cities.
As per IMS, Vietnam is one of the largest and fastest growing pharmaceutical market in the Region with a size of USD$ 3.8 billion. Searle started its operation in Vietnam in 2004 with its representative office based in Ho Chi Minh City. Currently, Searle Vietnam operates with its own marketing team and has an established product portfolio with leading products in Respiratory and Cardiovascular segments.
Cambodia, a culturally rich South-East Asian country has a fast-emerging economy with the youngest population in the region. Country’s pharmaceutical market size is approximately USD$300 million with a CAGR of 12%. Cambodia’s pharmaceutical market is heavily dependent upon imports from South Asia & ASEAN region.
Cambodia is among the newer operations in Searle’s Global Business Division, having started in 2011 on trading model with a strategic shift to marketing model in 2015.
Searle has now established a strong foothold in Cambodia pharmaceutical market, with continuous expansion & growth, having a young and motivated team & a highly diversified product-line in CardioMetabolic, Gastroenterology, Psychiatry, Hepatology, ENT, Pain Management & Pulmonology segments. As per the Import data 2017, Searle is the second largest exporter from Pakistan& the fastest growing company with CAGR of 155%.
Annual Sales Conference 2016
Activities of Cambodia
Kenya is one of the most developed countries in the East African region & famous for its wild life safari. Kenya pharmaceutical market is one of the fastest growing in the Region, at an approximate value of USD$750 million. Kenya PPB (Pharmacy and Poisons Board) is continuously upgrading its regulatory guidelines and is becoming one of the stringent authorities in the region.
Kenya has become hub for the multinational companies operating in the East-African Region with their regional office operating from Nairobi. Kenya’s major Pharmaceutical volumes are based on imports, while 15-20 local manufacturing facilities are fulfilling the tender business requirements.
Searle registered its plant and products way back in 1998 in Kenya & started its operations in January
2017 through its own dedicated marketing and sales team.
Laos has a population of approximately 7 million and is among the most naturally gifted countries in ASEAN Region. Opportunities of pharmaceutical business are widely spread across the country due to less competition compared to the region. It is over USD$100 million market, growing at a rapid pace.
Searle started its operations in Laos on trading model in 2016 and now operating with a good number of
products, adding a considerable value annually.
Activities of Laos
Philippines is the 3rd largest economy in the ASEAN region and 12th most populous country in the world, with a population of more than 100 million. The size of Pharmaceutical market is USD$3.6 Billion.
Searle established its legal entity under the name of Searle Pharmaceuticals Inc. in Philippines in 2011. Currently we have two business partners responsible for the distribution and marketing of Searle products in Philippines.
Searle is having its presence currently in Mauritius in Government and market-based tenders and generating reasonable revenue and planning to have our own marketing operation in near future.
Searle is in early stage of its operation in Maldives but in times to come, after the product registration and with our own marketing team, this country will also be a sizeable business contributing territory.
It is the fourth most populated country in the East-African region, with fastest growth in Pharmaceutical industry with market size of USD$ 450 million. Searle has around 9 registered products marketed through a local distributor. Searle is in the process of registering new products and planning to change its business model from trading to marketing through its own dedicated team.
SAFETY OF PRODUCTS
Humans vary in their biological reactions to medicinal products. This is why not all adverse reactions (side effects) associated with the use of medicinal products can be detected during clinical development, not even by the most comprehensive clinical trials.
Searle as a responsible organization focused on healthcare products safety. If you experience any unanticipated side effects, kindly report to
Please provide the following information in your email to ensure it is handled in a manner consistent with the applicable local laws:
- Name of the Searle medical product:
Description of when the patient started the medication, including dosing strength and frequency (amount and how often, e.g. 40mg twice daily). Please specify what are you using the product for. Any action taken with the medication (e.g. reduced dose, stopped) and impact of that action on the adverse event.
- The adverse event associated with the drug:
Description of details of the adverse event(s) and any additional product or procedure to treat the adverse event. Name of healthcare provider who provided treatment and contact information.
- Your name (optional) and occupation:
Please note that your personal identifying information (e.g. name, email address) will not be shared with the health authorities. Searle Pharmacovigilance unit may contact you for further information about the adverse event. If you do not wish to be contacted, you should indicate this in your email. Please specify your occupation.
- Information about the person who experienced the adverse event:
Any other medical conditions currently ongoing. Other medications currently taken (name, dosing strength, frequency, and when medication was started). Gender and age of the person taking medication (optional).